TRVI - CIK 0001563880
The table below shows Trevi Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $9.94M | $10.09M | $9.39M | $7.81M | $11.22M | $10.02M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $4.97M |
| $3.83M |
| $4.33M |
| $3.66M |
| $2.86M |
| $3.27M |
| Operating income | -$14.91M | -$13.92M | -$13.72M | -$11.47M | -$14.09M | -$13.29M |
| Income tax | -$20.00K | -$15.00K | -$21.00K | -$11.00K | -$31.00K | -$8.00K |
| Net income | -$13.19M | -$11.80M | -$12.30M | -$10.34M | -$13.24M | -$12.35M |
| EPS (diluted) | -$0.09 | -$0.08 | -$0.09 | -$0.09 | -$0.13 | -$0.12 |